Technical Analysis for APLS - Apellis Pharmaceuticals, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| See historical APLS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 50 DMA | Bearish | 0.00% | |
| 20 DMA Support | Bullish | 0.00% | |
| 20 DMA Support | Bullish | -1.90% | |
| Crossed Above 50 DMA | Bullish | -1.90% | |
| MACD Bullish Centerline Cross | Bullish | -1.90% | |
| 180 Bullish Setup | Bullish Swing Setup | -1.90% | |
| Stochastic Reached Overbought | Strength | -1.90% | |
| Overbought Stochastic | Strength | -1.90% | |
| Fell Below 50 DMA | Bearish | -0.73% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -0.73% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2019
- Sector: Healthcare
- Industry: Biotechnology
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.
Medicine Biopharmaceutical Clinical Medicine Organ Systems Macular Degeneration Chronic Obstructive Pulmonary Disease Autoimmune And Inflammatory Diseases Paroxysmal Nocturnal Hemoglobinuria Acquired Hemolytic Anemia Treatment Of Chronic Obstructive Pulmonary Disease Complement System Pnh
Medicine Biopharmaceutical Clinical Medicine Organ Systems Macular Degeneration Chronic Obstructive Pulmonary Disease Autoimmune And Inflammatory Diseases Paroxysmal Nocturnal Hemoglobinuria Acquired Hemolytic Anemia Treatment Of Chronic Obstructive Pulmonary Disease Complement System Pnh
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more APLS news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 24.84 |
| 52 Week Low | 11.45 |
| Average Volume | 445,457 |
| 200-Day Moving Average | 16.787 |
| 50-Day Moving Average | 19.2526 |
| 20-Day Moving Average | 19.053 |
| 10-Day Moving Average | 18.876 |
| Average True Range | 1.0207 |
| ADX | 10.63 |
| +DI | 20.0677 |
| -DI | 17.712 |
| Chandelier Exit (Long, 3 ATRs ) | 17.3979 |
| Chandelier Exit (Short, 3 ATRs ) | 20.4221 |
| Upper Bollinger Band | 20.1649 |
| Lower Bollinger Band | 17.9411 |
| Percent B (%b) | 0.52 |
| BandWidth | 11.671653 |
| MACD Line | 0.0206 |
| MACD Signal Line | -0.0217 |
| MACD Histogram | 0.0423 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 20.69 | ||||
| Resistance 3 (R3) | 20.76 | 20.30 | 20.43 | ||
| Resistance 2 (R2) | 20.30 | 19.90 | 20.27 | 20.34 | |
| Resistance 1 (R1) | 19.70 | 19.64 | 19.47 | 19.63 | 20.25 |
| Pivot Point | 19.24 | 19.24 | 19.13 | 19.21 | 19.24 |
| Support 1 (S1) | 18.64 | 18.84 | 18.41 | 18.57 | 17.95 |
| Support 2 (S2) | 18.18 | 18.58 | 18.15 | 17.86 | |
| Support 3 (S3) | 17.58 | 18.18 | 17.78 | ||
| Support 4 (S4) | 17.51 |
